Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206709 | 0.91 | SIRT6 (0.46) | ALDH1A1CYP2D6L3MBTL1LMNASIRT6 | |
| SCHEMBL2209685 | 0.87 | ALDH1A1 (0.43) | ALDH1A1CYP2D6L3MBTL1LMNASIRT6 | |
| SCHEMBL2201835 | 0.84 | SIRT6 (0.53) | ALDH1A1LMNASIRT6CHEK1MAPT | |
| SCHEMBL2208118 | 0.82 | IGF1R (0.42) | ALDH1A1CYP2D6L3MBTL1LMNASIRT6 | |
| SCHEMBL2206543 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LMNASIRT6CHEK1ABCB1 | |
| SCHEMBL30868397 | 0.77 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1LMNASIRT6CHEK1 | |
| SCHEMBL6181269 | 0.76 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1LMNASIRT6CHEK1 | |
| SCHEMBL2207405 | 0.75 | CHRM2 (0.47) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL311532 | 0.75 | SIGMAR1 (0.48) | ALDH1A1CYP2D6L3MBTL1LMNASIRT6 | |
| SCHEMBL2208088 | 0.73 | ADRA2A (0.46) | ALDH1A1LMNASIRT6CHEK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | ALDH1A1 238/4885CYP2D6 2229/4885L3MBTL1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.